Schering Aktiengesellschaft

Evestra, Inc.

Bayer Schering Pharma Ag

Everstra, Inc.

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Klaus Nickisch

Henry Laurent

Rudolf Wiechert

Dieter Bittler

Bindu Santhamma

Hareesh Nair

Walter Elger

Gregor Haffer

Wolfgang Losert

Johannes Platzek

William C Lumma, Jr

Alfred Weber

Ronald A Wohl

Jurgen Westermann

Heinz Gries

Bernd Raduchel

Orlin Petrov

Mario Kennecke

James W Cessac

Thomas K Morgan, Jr

Helmut Borner

Randall E Lis

Ulf Tilstam

Thomas Schmitz

Frederick Meece

Gulzar Ahmed

Heribert Schmitt-Willich

Karl Petzoldt

Jorge Casals-Stenzel

Ralph Rohde

Ralf Wyrwa

Kesavaram Narkunan

Jean-Claude Hilscher

Wolfgang Kubler

Annette Prelle

Stanley S Greenberg

Thomas Frenzel

Martin Haberey

Klaus Annen

Sybille Beier

Hans Bauer

Hubert Vogler

Pemmaraju Narasimha Rao

Andreas Muhler

Peter Esperling

Paul-Eberhard Schulze

Robert C Nickolson

Julius Deutsch

Petra Rach

Michael Harre

Uwe Klages

Hanfried Arnold

Rudolf Weichert

Kunhard Pollow

Anne Marie Simmons

Jörg-Thorsten Mohr

Mario Kennekke

Heidi Hummel-Marquardt

Klaus Dieter Graske

Ulf Tisltam

Baishakhi Das

Kirk Acosta

Pemmaranu N Rao

Heidi Hummel-Maquardt

Reiner Wierzchowski

Jean C Hilscher

Baishakhi Debnath

Pemmaraju N Rao

James Cessac

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.

Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

Described herein are progestin compounds that have extended release rates and that can be used without an estrogen to produce a contraceptive state.

Longer-acting progestin prodrug contraceptives

Various prodrug compounds having the general structure: Active agent&#x2014;(acid)-(linker)&#x2014;SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Pro-drug forming compounds

Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.

Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer

Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.

Imidazolyl progesterone antagonists

Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.

Progesterone antagonists

Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.

Methods for the preparation of drospirenone

Described herein are 3-(6,6-ethylene-17&#x3b2;-hydroxy-3-oxo-17&#x3b1;-pregna-4-ene-17&#x3b1;-yl)propionic acid &#x3b3;-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.

Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones

Described herein are bismethylene-17&#x3b1; carbolactone derivatives having progestational and/or antimineralocorticoid and/or aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.

Bismethylene-17A carbolactones and related uses

The present invention generally relates to a fludarabine-phosphate with a purity of at least 99.5%.

Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%

Process for the production of drospirenone (6&#x3b2;,7&#x3b2;; 15&#x3b2;,16&#x3b2;-dimethylene-3-oxo-17&#x3b1;-pregn-4-ene-21,17-carbolactone, DRSP) (1) and 7&#x3b1;-(3-hydroxy-1-propyl)-6&#x3b2;,7&#x3b2;; 15&#x3b2;,16&#x3b2;-dimethylene-5&#x3b2;-androstane-3&#x3b2;,5,17&#x3b2;-triol (ZK 92836) and 6&#x3b2;,7&#x3b2;; 15&#x3b2;,16&#x3b2;-dimethylene-5&#x3b2;-hydroxy-3-oxo-17&#x3b1;-androstane-21,17-carbolactone (ZK 90965) as intermediate products of the process.

PROCESSING FOR PRODUCING OF DROSPIRENONE (6&#x3b2;, 7&#x3b2;, 15&#x3b2;, 16&#x3b2;-DIMETHYLENE-3-OXO-17&#x3b1;-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7&#x3b1;-(3-HYDOXY-1-PROPLY)-6&#x3b2;, 7&#x3b2;; 15&#x3b2;, 16&#x3b2;-DIMETHYLENE-5&#x3b2;-ANDROSTANE-3&#x3b2;, 5,17&#x3b2;-TRIOL(ZK 92836) AND 6&#x3b2;, 7&#x3b2;; 15&#x3b2;, 16&#x3b2;-DIMETHYLENE-5&#x3b2;-HYDROXY

Process for production drospirenone and intermediate products of the

A reduced temperature crystallization process for the obtaining fludarabine phosphate at a purity of at least 99.5%.

Process for the production of fludarabine-phosphate lithium, sodium,

Growing community of inventors

Berlin, Germany

Klaus Nickisch